

APRIL

Date	Headline and Source	Link	Summary
1 st April	CDSCO Panel grants Novo Nordisk's Protocol Amendment Proposal For Antidiabetic Drug Semaglutide study Medical Dialogues, April 01, 2024	CDSCO Panel grants Novo Nordisk's Protocol Amendment Proposal For Antidiabetic Drug Semaglutide study	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novo Nordisk's Protocol Amendment proposal for the antidiabetic drug Semaglutide study. This came after the drug maker Novo Nordisk presented protocol amendment version 5.0 dated 07 September 2023 protocol No: NN99244437.
2 nd April	Reputation key to curbing unethical marketing, name and shame policy just the beginning: Pharma Secy CNBC TV18, April 02, 2024	Reputation key to curbing unethical marketing, name and shame policy just the beginning: Pharma Secy	Regarding the meeting participants, Chawla noted, It comprised representatives from key pharma associations, including the Indian Pharmaceutical Alliance (IPA) representing the largest 25 Indian pharma companies; OPPI, which serves a similar role for multinational pharma companies in India; IDMA, a significant association comprising 1,100 medium-sized drug manufacturers across the nation, and the Bulk Drug Manufacturers Association, representing around 300 bulk drug manufacturers nationwide.
2 nd April	Sanofi plans to launch 1 or 2 products in India every year The Economic Times, April 02, 2024	Sanofi plans to launch 1 or 2 products in India every year	Sanofi is committed to the Indian market and plans to launch 1 or 2 products every year from its innovation portfolio in the country, said a top executive of the French drugmaker. The company is in the process of launching its much-awaited product Soliqua, a combination of insulin glargine 100 units/mL and lixisenatide, in India in clinical trials, Soliqua has shown improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia).

<p>2nd April</p>	<p>Sanofi to bring 5 of its bestselling drugs to India Live Mint, April 02, 2024</p>	<p>Sanofi to bring 5 of its bestselling drugs to India</p>	<p>French pharmaceutical major Sanofi is looking to launch as many as five of its bestselling global drugs in India as the company looks to revamp its strategy in the country. This push comes against the backdrop of Sanofi's longer-term ambitions to widen its presence in India.</p>
<p>3rd April</p>	<p>French pharma major Sanofi plans first-in-class drug launches in India Money Control, April 03, 2024</p>	<p>French pharma major Sanofi plans first-in-class drug launches in India</p>	<p>French pharmaceutical giant Sanofi India is gearing up for a series of first-in-class drug launches in the Indian market this year, according to a statement from a top company official. Rodolfo Hrosz, Managing Director of Sanofi India Limited, told Moneycontrol in an interview that the company has planned these launches from June onwards.</p>
<p>4th April</p>	<p>Centre to adopt name and shame policy to curb unethical marketing practices Medical Buyer, April 04, 2024</p>	<p>Centre to adopt name and shame policy to curb unethical marketing practices</p>	<p>Regarding the meeting participants, Chawla noted, It comprised representatives from key pharma associations, including the Indian Pharmaceutical Alliance (IPA) representing the largest 25 Indian pharma companies; OPPI, which serves a similar role for multinational pharma companies in India; IDMA, a significant association comprising 1,100 medium-sized drug manufacturers across the nation, and the Bulk Drug Manufacturers Association, representing around 300 bulk drug manufacturers nationwide.</p>
<p>5th April</p>	<p>Sanofi gets nod for injectable Polio vaccine The Economic Times, April 05, 2024</p>	<p>Sanofi gets nod for injectable Polio vaccine</p>	<p>French drugmaker Sanofi has said it obtained approval for IMOVAX-Polio, an injectable vaccine, from the Indian authorities. The announcement comes a day after ET reported that the company had ceased production of its Shan-IPV vaccines in India, which may lead to a potential shortage in the country.</p>

<p>5th April</p>	<p>Centre of Excellence to come up at Manipal Hospital The New Indian Express, April 05, 2024</p>	<p>Centre of Excellence to come up at Manipal Hospital</p>	<p>Establishing a comprehensive healthcare ecosystem within the hospital to prevent vaccine-preventable diseases (VPDs), Manipal Hospital in Vijayawada announced its collaboration with Pfizer, establishing a Centre of Excellence (CoE) and a hub for adult vaccination.</p>
<p>6th April</p>	<p>CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal For COPD Drug Study Medical Dialogues, April 06, 2024</p>	<p>CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal For COPD Drug Study</p>	<p>The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by the drug major AstraZeneca for the drug MEDI3506 (Tozorakimab), an antiIL33 antibody.</p>
<p>6th April</p>	<p>For Roche, India among 5 fastest-growing markets The Times of India, April 06, 2024</p>	<p>For Roche, India among 5 fastest-growing markets</p>	<p>Amid a trend of reduced exposure and sluggish performance among most pharma MNCs in India, Swiss biotech biggie Roche is bucking the trend India is now among the five fastest-growing markets for Roche and its revenues (excluding Covid portfolio) more than doubled over last three years, strengthening its trust in the Indian market, Roche Pharma India MD and CEO V Simpson Emmanuel told TOI.</p>
<p>6th April</p>	<p>Sanofi gets nod for new polio vaccine in India The Economic Times, April 06, 2024</p>	<p>Sanofi gets nod for new polio vaccine in India</p>	<p>Drug firm Sanofi on Friday said it has obtained approval for IMOVAX-Polio, an alternative injectable vaccine, to replace the Inactivated Polio Vaccine (IPV) ShanIP in India. IMOVAX-Polio is an alternative IPV vaccine that has been used in more than 100 countries for over 40 years, a Sanofi India spokesperson told PTI.</p>
<p>6th April</p>	<p>Dr Reddy's, Bayer partner to market second brand of Vericiguat in India Business Standard, April 06, 2024</p>	<p>Dr Reddy's, Bayer partner to market second brand of Vericiguat in India</p>	<p>Dr Reddy's Laboratories Ltd and Bayer have entered into a partnership for the marketing and distribution of a second brand of Vericiguat in India, the former announced in a press release on Friday. Bayer has granted</p>

			nonexclusive rights to Dr Reddy's under the brand name Gantra.
7 th April	Second brand of heart failure drug from Bayer and Dr Reddy's The Times of India, April 07, 2024	Second brand of heart failure drug from Bayer and Dr Reddy's	Dr Reddy's, Bayer join hands to roll out 2nd brand of heart failure drug Vericiguat in India Dr Reddy's and Bayer collaborate to introduce Vericiguat as Gantra in India, aiming to reduce cardiovascular death risk. The partnership highlights innovative solutions for heart failure management, focusing on wider accessibility in various towns across India.
8 th April	Sanofi Eyes Accelerated Growth in India The Economic Times, April 08, 2024	Sanofi Eyes Accelerated Growth in India	Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic drug firms, according to a top company official.
8 th April	Sanofi outlines India growth strategy; plans new launches, collaboration The Financial Express, April 08, 2024	Sanofi outlines India growth strategy; plans new launches, collaboration	French pharma major, Sanofi is aiming to secure its fair share of the Indian pharmaceutical market. Their plans involve the introduction of new drugs, boosting localisation efforts and expanding the market reach of existing brands through partnerships with local drug firms, according to a top company official.
9 th April	Sanofi's new polio vaccine gets nod in India amid speculations of potential shortage The Financial Express, April 09, 2024	Sanofi's new polio vaccine gets nod in India amid speculations of potential shortage	French drugmaker Sanofi has obtained approval for IMOVAX-Polio, an alternative injectable vaccine. According to a report by PTI, this new vaccine will replace the Inactivated Polio Vaccine (IPV) ShanIP in India. IMOVAX-Polio is an alternative IPV vaccine that has been used in more than 100 countries for over 40 years, a Sanofi India spokesperson told PTI.
10 th April	CDSCO Panel Approves Novo Nordisk's Protocol Amendment Proposal for CagriSema Study	CDSCO Panel Approves Novo Nordisk's Protocol Amendment Proposal for CagriSema Study	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novo Nordisk's proposal for

	Medical Dialogues, April 10, 2024		the protocol amendment of the antidiabetic drug combination Cagrilintide and Semaglutide (CagriSema) study.
11 th April	Roche Diagnostics India launches heart failure test for diabetics as point of care device Bio Spectrum, April 11, 2024	Roche Diagnostics India launches heart failure test for diabetics as point of care device	Roche Diagnostics India has announced the launch of its point of care NT pro BNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). This breakthrough innovation is designed to bring testing closer to clinics and revolutionize patient care.
11 th April	Roche Diagnostics India s Heart Failure Test for Diabetics Now Available on its Point of care Device The Print, April 11, 2024	Roche Diagnostics India s Heart Failure Test for Diabetics Now Available on its Point of care Device	Roche Diagnostics India announces the launch of its point of care Natron test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). This breakthrough innovation is designed to bring testing closer to clinics and revolutionize patient care.
12 th April	CDSCO Panel grants AstraZeneca s proposal for withdrawing specific Indications of Olaparib Tablets Medical Dialogues, April 12, 2024	CDSCO Panel grants AstraZeneca s proposal for withdrawing specific Indications of Olaparib Tablets	Reviewing the Clinical evidence presented by drug major AstraZeneca, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the withdrawal of the indication of Olaparib 100mg and 150mg tablets in the treatment of patients with gBRCA mutation and advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
12 th April	Roche Diagnostics India launches point of care NT-proBNP test for screening diabetes patients at cardiovascular diseases risk Medical Dialogues, April 12, 2024	Roche Diagnostics India launches point of care NT-proBNP test for screening diabetes patients at cardiovascular diseases risk	Roche Diagnostics India has announced the launch of its point of care NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). This breakthrough innovation is designed to bring testing closer to clinics and revolutionise patient care.

13 th April	Foreign pharma firms seek clarity on doctors attending events abroad under new ethical practices rules The Print, April 13, 2024	Foreign pharma firms seek clarity on doctors attending events abroad under new ethical practices rules	Anil Matai, director general of the Organization of Pharmaceutical Producers of India (OPPI), a network of research based global pharmaceutical companies in India, said the organization had reached out to the government a few days ago to understand what happens in cases where medical conferences are organized by firms headquartered abroad.
13 th April	Roche Diagnostics India launches heart failure test for diabetics in India The Financial Express, April 13, 2024	Roche Diagnostics India launches heart failure test for diabetics in India	According to the company, this breakthrough innovation is designed to bring testing closer to clinics and revolutionize patient care. The claim extension of the NTproBNP biomarker, available exclusively on the cobas h 232 system, aims to provide faster, more efficient diagnosis and management of HF in patients with type 2 diabetes (T2D), the company said in a statement.
13 th April	Roche gets CE Mark for companion diagnostic to identify patients with HER2low metastatic breast cancer eligible for Enhertu Medical Dialogues, April 13, 2024	Roche gets CE Mark for companion diagnostic to identify patients with HER2low metastatic breast cancer eligible for Enhertu	Tucson: Roche has announced the approval of the CE Mark for the VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU (trastuzumab erotica) may be considered as a targeted treatment.
13 th April	Roche Diagnostics India launches NTproBNP test for diabetes patients at risk of CVD ET Health World, April 13, 2024	Roche Diagnostics India launches NTproBNP test for diabetes patients at risk of CVD	Mumbai: Roche Diagnostics India announces the launch of its point of care (PoC) NTproBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). This breakthrough innovation is designed to bring testing closer to clinics and revolutionize patient care.
14 th April	Roche Diagnostics India Launches Point of Care Heart Failure Test For Diabetics	Roche Diagnostics India Launches Point of Care Heart Failure Test For Diabetics	Roche Diagnostics India has introduced a groundbreaking advancement in healthcare with the launch of its point of care NT-proBNP test, specifically designed

	BW Healthcare World, April 14, 2024		to screen diabetes patients for cardiovascular diseases (CVD) such as heart failure (HF). This innovative solution aims to enhance testing efficiency and improve disease management, bringing transformative benefits to patient care.
15 th April	CDSCO Panel Approves Roche's Protocol Amendment Proposal For Anticancer Drug Atezolizumab, Lenvatinib, and Sorafenib Study Medical Dialogues, April 15, 2024	CDSCO Panel Approves Roche's Protocol Amendment Proposal For Anticancer Drug Atezolizumab, Lenvatinib, and Sorafenib Study	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Roche s proposal for the protocol amendment of the Clinical trial titled A Study of Atezolizumab with Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated with Atezolizumab and Bevacizumab.
15 th April	CDSCO Panel Approves J&J's Protocol Amendment Proposal For Amivantamab, Lazertinib combination Medical Dialogues, April 15, 2024	CDSCO Panel Approves J&J's Protocol Amendment Proposal For Amivantamab, Lazertinib combination	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Johnson & Johnson's proposal for the protocol amendment of the fixed-dose combination (FDC) anticancer drug Amivantamab Plus Lazertinib.
16 th April	-	-	-
17 th April	-	-	-
18 th April	-	-	-
19 th April	-	-	-
20 th April	Enforceable Marketing Code for Pharma and Medical Device Companies Bar and Bench, April 20, 2024	Enforceable Marketing Code for Pharma and Medical Device Companies	As lawyers advising healthcare companies on issues related to marketing practices over the years, the legal advice was primarily based on the good practices set out in the voluntary 2015. Code, and the code of pharmaceutical practices issued by the Organization of Pharmaceutical Producers of India (OPPI Code).
21 st April	-	-	-

22 nd April	Novartis Gets CDSCO Panel Nod to Study anticancer drug Ribociclib Medical Dialogues, April 22, 2024	Novartis Gets CDSCO Panel Nod to Study anticancer drug Ribociclib	The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase IV clinical study of the anticancer drug Ribociclib (LEE011).
22 nd April	Novo Nordisk Gets CDSCO Panel Nod to Study new medicine NNC05190130 Medical Dialogues, April 22, 2024	Novo Nordisk Gets CDSCO Panel Nod to Study new medicine NNC05190130	The drug major Novo Nordisk has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase 2 clinical trial for the new antidiabetic drug NNC05190130.
22 nd April	CDSCO Panel Approves Eli Lilly s protocol amendment proposal for Adjuvant Imlunestrant vs Standard Adjuvant study Medical Dialogues, April 22, 2024	CDSCO Panel Approves Eli Lilly s protocol amendment proposal for Adjuvant Imlunestrant vs Standard Adjuvant study	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Eli Lilly's protocol amendment proposal for Adjuvant Imlunestrant vs Standard Adjuvant study.
23 rd April	-	-	-
24 th April	Govt expands committee for drug and medical device pricing reforms, includes more industry representation The Economic Times, April 24, 2024	Govt expands committee for drug and medical device pricing reforms, includes more industry representation	The committee now includes special invitees from the industry including director general of Organisation of Pharmaceutical Producers of India (OPPI), managing director, US-India Strategic Partnership Forum (USISPF), industry representatives like Medical Technology Association of India (MTal), Confederation of Indian Industry (CII), forum coordinator of Association of Indian Medical Device Industry (AiMed), Federation of Pharma Entrepreneurs (FOPE), among others.
24 th April	DigiPharmaX Awards 2024 Celebrating Pharma Excellence The Week, April 24, 2024	DigiPharmaX Awards 2024 Celebrating Pharma Excellence	A distinguished panel of judges, including Anil Matai (COO & Director General OPPI), Girisan Kariangal (MD Menarini India), Girdhar Balwani (Independent

			Director Cadila Pharmaceuticals), Sanjiv Navangul (MD & CEO Bharat Serum and Vaccines), and Vijayesh Gupta (COO Cadila Pharmaceuticals), lent their expertise to assess the prizes.
24 th April	Roche signs MoU with VinCense to augment access to diabetes care in Tamil Nadu BioSpectrum India, April 24, 2024	Roche signs MoU with VinCense to augment access to diabetes care in Tamil Nadu	Roche has signed a Memorandum of Understanding (MoU) with VinCense, a digital health monitoring offering by MedloTek Health Systems. Under the terms of the agreement, the two companies aim to implement 3 programmes in Madurai district of Tamil Nadu (i) screening 100,000 individuals over the next two years for diabetes, hypertension, obesity etc. (ii) intervention for uncontrolled diabetes mellitus management (iii) intervention for tuberculosis diabetes mellitus comorbidity management.
25 th April	Centre expands committee participation to usher in drugs pricing reforms Live Mint, April 25, 2024	Centre expands committee participation to usher in drugs pricing reforms	The new inductees are: Director General of the Organisation of Pharmaceutical Producers of India (OPPI), Managing Director, USINDIA Strategic Partnership Forum (USISPF), Chairman, Medical Technology Association of India (MTaI), Director General, Confederation of Indian Industry (CII), Director, US India Business Council (USIBC), Secretary General, Federation of Indian Chambers of Commerce and Industry (FICCI), Forum Coordinator, Association of Indian Medical Device Industry (AiMED), Executive Director, Federation of Pharma Entrepreneurs (FOPE), Representative of AdvaMed, Representative of ADMI (Association of Diagnostic Manufacturers of India), and Representative of BDMAI (Bulk Drugs Manufacturers Association of

			India), Representative of ASSOCHAM.
25 th April	Govt expands committee for drugs, medical devices pricing reforms Business Standard, April 25, 2024	Govt expands committee for drugs, medical devices pricing reforms	The committee, which was constituted by the Department of Pharmaceuticals on March 12, will now have representation from industry bodies such as the Confederation of Indian Industries (CII), the Organisation of Pharmaceutical Producers of India (OPPI), and the US-India Strategic Partnership Forum (USISPF), among others.
25 th April	DoP broadens list of special invitees into committee constituted to reform pricing framework PharmaBiz, April 25, 2024	DoP broadens list of special invitees into committee constituted to reform pricing framework	The broadened list of special invitees include director general of Organisation of Pharmaceutical Producers of India (OPPI), managing director, US-India Strategic Partnership Forum (USISPF), chairman of Medical Technology Association of India (MTAI), director general, Confederation of Indian Industry (CII), director, US India Business Council (USIBC), secretary general, Federation of Indian Chambers of Commerce and Industry (FICCI), forum coordinator, Association of Indian Medical Device Industry (AiMeD), executive director of Federation of Pharma Entrepreneurs (FOPE), representatives of Advamed, Association of Diagnostic Manufacturers of India (ADMI), Bulk Drugs Manufacturers Association of India (BDMAI), and Associated Chambers of Commerce & Industry of India (Assocham).
25 th April	GSK Gets CDSCO Panel Nod to Study antimalarial drug Tafenoquine Medical Dialogues, April 25, 2024	GSK Gets CDSCO Panel Nod to Study antimalarial drug Tafenoquine	The pharmaceutical major GSK has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical trial of the antimicrobial drug Tafenoquine

			Tablets 50 mg /150 mg, used to prevent and to treat malaria.
25 th April	Roche and VinCense Join Forces to Combat Diabetes Epidemic in Tamil Nadu Elets eHealth E Health, April 25, 2024	Roche and VinCense Join Forces to Combat Diabetes Epidemic in Tamil Nadu Elets eHealth	Roche, a global leader in healthcare, has entered into a strategic partnership with VinCense, a digital health monitoring platform by MedloTek Health Systems, to tackle the rising prevalence of diabetes and associated metabolic noncommunicable diseases (NCDs) in Tamil Nadu, India.
26 th April	Eli Lilly Gets CDSCO Panel Nod to Study Lepodisiran Medical Dialogues, April 26, 2024	Eli Lilly Gets CDSCO Panel Nod to Study Lepodisiran	The drug major Eli Lilly has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical trial for Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein.
27 th April	Balancing IP Laws and Generic Manufacturing to Propel, Health News The Economic Times, April 27, 2024	Balancing IP Laws and Generic Manufacturing to Propel, Health News	A recent report of a study conducted by the Organization of Pharmaceutical Producers of India (OPPI) and EY Parthenon has underscored the immense potential of the Indian pharmaceutical industry to not only meet but surpass expectations.
28 th April	CDSCO Panel Grants Novartis Protocol Amendment Proposal For lanalumab Medical Dialogues, April 28, 2024	CDSCO Panel Grants Novartis Protocol Amendment Proposal For lanalumab	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novartis protocol amendment proposal for the drug lanalumab (VAY736). This came after Novartis presented protocol amendment version 03 dated 27 Apr 2023 and protocol amendment 04 dated 14 Dec 2023, protocol No. CVAY736I12301.
28 th April	'India becoming attractive for clinical trials' The Pioneer, April 28, 2024	'India becoming attractive for clinical trials'	Data from 2017 to 2023 shows that phase two and phase three clinical trials are growing at about 15 per cent to 18 per cent in India. This is primarily because of the 10 modifications done to the Drugs

			and Cosmetics Act of 1940, according to Badhri Srinivasan, head of Global Clinical Operations, Novartis. Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
29 th April	India becoming attractive for clinical trials, says pharma industry leaders ET Health World, April 29, 2024	India becoming attractive for clinical trials, says pharma industry leaders	We foresee a number of opportunities that we can start slowly with one to two pivotal trials in the next year or so and then build that experience organically, Sheikh said. Dr. Christopher Corsico, Global Head of Development, GSK, said that many companies have built a huge infrastructure in India because of the talented population there to help build and run the operational component of clinical trials.
30 th April	India becoming attractive for clinical trials: Pharma industry leaders Medical Dialogues, April 30, 2024	India becoming attractive for clinical trials: Pharma industry leaders	Dr. Uli Broedl, senior vice president and head of Global Clinical Development, at Boehringer Ingelheim, said India now offers huge opportunities. It is an absolute misperception that quality was poor. Infrastructure stepped up. We are currently at Boehringer Ingelheim running a large phase three global programme, where India participates in obesity.
